Aspirin side effects in alcoholics
This article was originally published in The Tan Sheet
Executive Summary
FDA denies Aspirin Foundation of America's request for access to the raw data and protocols for studies on aspirin and gastrointestinal bleeding submitted by McNeil to the Nonprescription Drugs Advisory Committee just prior to the panel's June 29 meeting on acetaminophen-associated liver toxicity. Office of OTC Drug Evaluation Director Michael Weintraub told AFA in a July 20 letter that some of the information may be made available later under FDA's OTC feedback policy. At McNeil's request, the submission to the committee has not been released to the public.
|
FDA denies Aspirin Foundation of America's request for access to
the raw data and protocols for studies on aspirin and
gastrointestinal bleeding submitted by McNeil to the
Nonprescription Drugs Advisory Committee just prior to the panel's
June 29 meeting on acetaminophen-associated liver toxicity. Office
of OTC Drug Evaluation Director Michael Weintraub told AFA in a
July 20 letter that some of the information may be made available
later under FDA's OTC feedback policy. At McNeil's request, the
submission to the committee has not been released to the
public. |